文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

吸入糖皮质激素联合长效抗胆碱能药与哮喘控制的关系

Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA · 2018-01-01

该系统评价与荟萃分析纳入15项随机临床试验共7122例控制不佳的持续性哮喘患者,评估在吸入糖皮质激素基础上加用LAMA的疗效。与安慰剂相比,加用LAMA可降低需全身糖皮质激素的急性发作风险(RR 0.67,95%CI 0.48–0.92);但与加用LABA相比无显著改善,三联疗法亦未显著降低发作风险。

要点

  • 吸入糖皮质激素加用LAMA较安慰剂降低需全身激素的急性发作风险。
  • 加用LAMA在降低发作风险上未显著优于加用LABA。
  • 吸入糖皮质激素+LABA基础上加LAMA的三联疗法未显著降低发作风险。

核心结论

  • 在吸入糖皮质激素基础上加用LAMA较安慰剂与哮喘急性发作风险降低相关,但该获益可能不大于加用LABA,三联疗法未与更低的发作风险相关。

研究设计与样本

  • 纳入15项随机临床试验,共7122例控制不佳的持续性哮喘患者,采用随机效应模型计算RR、RD与MD及95%CI。

主要发现

  • 加用LAMA对比安慰剂(在吸入糖皮质激素基础上)与需全身糖皮质激素的急性发作风险显著降低相关:RR 0.67(95%CI 0.48–0.92),RD -0.02(95%CI -0.04–0.00)。
  • 加用LAMA对比加用LABA(在吸入糖皮质激素基础上)与急性发作风险无显著改善相关:RR 0.87(95%CI 0.53–1.42),RD 0.00(95%CI -0.02–0.02),其他结局亦无显著改善。
  • 三联疗法对比吸入糖皮质激素+LABA与急性发作风险改善无显著相关:RR 0.84(95%CI 0.57–1.22),RD -0.01(95%CI -0.08–0.07)。

关键数值与推荐

  • 需全身糖皮质激素的急性发作:加用LAMA vs 安慰剂 RR 0.67(95%CI 0.48–0.92)。
  • 急性发作风险:加用LAMA vs 加用LABA RR 0.87(95%CI 0.53–1.42)。
  • 急性发作风险:三联疗法 vs 吸入糖皮质激素+LABA RR 0.84(95%CI 0.57–1.22)。

临床怎么用

  • 对控制不佳的持续性哮喘,可考虑在吸入糖皮质激素基础上加用LAMA以降低需全身激素的急性发作风险。
  • 选择加用LAMA或LABA时应结合患者具体情况,因LAMA获益可能不优于LABA。
  • 不宜仅以降低急性发作风险为目的在吸入糖皮质激素+LABA基础上常规加用LAMA。

局限性

  • 纳入研究多数评估加用LAMA对比安慰剂或对比LABA,其他对照比较的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Long-acting muscarinic antagonists (LAMAs) are a potential adjunct therapy to inhaled corticosteroids in the management of persistent asthma. OBJECTIVE: To conduct a systematic review and meta-analysis of the effects associated with LAMA vs placebo or vs other controllers as an add-on therapy to inhaled corticosteroids and the use of a LAMA as add-on therapy to inhaled corticosteroids and long-acting β-agonists (LABAs; hereafter referred to as triple therapy) vs inhaled corticosteroids and LABA in patients with uncontrolled, persistent asthma. DATA SOURCES: MEDLINE, EMBASE, Cochrane databases, and clinical trial registries (earliest date through November 28, 2017). STUDY SELECTION: Two reviewers selected randomized clinical trials or observational studies evaluating a LAMA vs placebo or vs another controller as an add-on therapy to inhaled corticosteroids or triple therapy vs inhaled corticosteroids and LABA in patients with uncontrolled, persistent asthma reporting on an outcome of interest. DATA EXTRACTION AND SYNTHESIS: Meta-analyses using a random-effects model was conducted to calculate risk ratios (RRs), risk differences (RDs), and mean differences (MDs) with corresponding 95% CIs. Citation screening, data abstraction, risk assessment, and strength-of-evidence grading were completed by 2 independent reviewers. MAIN OUTCOMES AND MEASURES: Asthma exacerbations. RESULTS: Of 1326 records identified, 15 randomized clinical trials (N = 7122 patients) were included. Most trials assessed adding LAMA vs placebo or LAMA vs LABA to inhaled corticosteroids. Adding LAMA vs placebo to inhaled corticosteroids was associated with a significantly reduced risk of exacerbation requiring systemic corticosteroids (RR, 0.67 [95% CI, 0.48 to 0.92]; RD, -0.02 [95% CI, -0.04 to 0.00]). Compared with adding LABA, adding LAMA to inhaled corticosteroids was not associated with significant improvements in exacerbation risk (RR, 0.87 [95% CI, 0.53 to 1.42]; RD, 0.00 [95% CI, -0.02 to 0.02]), or any other outcomes of interest. Triple therapy was not significantly associated with improved exacerbation risk vs inhaled corticosteroids and LABA (RR, 0.84 [95% CI, 0.57 to 1.22]; RD, -0.01 [95% CI, -0.08 to 0.07]). CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, the use of LAMA compared with placebo as add-on therapy to inhaled corticosteroids was associated with a lower risk of asthma exacerbations; however, the association of LAMA with benefit may not be greater than that with LABA. Triple therapy was not associated with a lower risk of exacerbations.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sobieraj DM, Baker WL, Nguyen E, et al. Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 29554174. doi:10.1001/jama.2018.2757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。